Skip to content

Asking People With Psoriasis About Lifestyle and Eating

The APPLE Study; a Cross-sectional Study Exploring Diet, Life-style Patterns and Psoriasis Severity

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05448352
Acronym
APPLE
Enrollment
358
Registered
2022-07-07
Start date
2022-06-18
Completion date
2024-01-08
Last updated
2024-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Keywords

Diet, Lifestyle, Sleep, Physical Acitivty, Wellbeing

Brief summary

The APPLE Study aims to understand if specific diet and lifestyle patterns are present in individuals with psoriasis and if these factors are correlated with psoriasis severity.

Detailed description

Prospective participants will be invited to read an information sheet and provide informed consent. Once informed consent is obtained, participants will be screened for eligibility with a short online screening questionnaire. Upon successful completion, participants will be directed to start the online multiple-choice survey with questions on psoriasis, diet and lifestyle patterns and complete a 4-day diet diary.

Interventions

None listed

Sponsors

Psoriasis Association
CollaboratorUNKNOWN
King's College London
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Adults (18 years of age or older) Dermatologist diagnosis of psoriasis Residents in the United Kingdom (UK) Fluent in English

Exclusion criteria

Minors (17 years of age or younger) Not medically diagnosed with Psoriasis Non-UK residents

Design outcomes

Primary

MeasureTime frameDescription
self-assessed Simplified Psoriasis IndexBaselineThe self-assessed Simplified Psoriasis Index measures psoriasis severity as a joint score of 3 categories. Severity; a 3-point scale will measure the severity of skins lesions on 10 body parts. 0=minimal, +/-=noticeable. + =extensive. A 5-point scale ranging from 0=clear to 5=intensely inflamed skin will measure the overall state of psoriasis. Psychosocial; a 10 point scale ranging from 0=not at all to 10=very much will indicate the extent to which psoriasis is affecting day-to-day life. Intervention; participants will need to indicate each psoriasis treatment that is being received. 1 point per treatment. The sa-PSI will generate a total score out of 70. The higher the score, the greater the severity of psoriasis.
The Dermatology Life Quality Index (DLQI)BaselineThis index measures the impact of psoriasis on day-to-day routines as well as on psychological and social fronts. Responses to questions are scored as follows: very much (3 points), a lot (2 points), a little (1 point), not at all/not relevant (0 points). The DLQI provides a score between 0-30. The score range is interpreted as follows: 0-1 points = no effect at all on the participants life, 2-5 points = small effect on participant's life, 6-10 points = moderate effect on participant's life, 11-20 = very large effect on participant's life and 21-30 = extremely large effect on participant's life.
DietBaselineThe Twins United Kingdom (TwinsUK) modified European Prospective Investigation into Cancer Food Frequency Questionnaire (EPIC FFQ) will assess dietary intake. This FFQ will provide an overview of the consumption of 131- food items over the past 12 months. Each food item will be rated on a 9 point scale as follows: Never or less than once a month, 1-3 times per month, Once a week, 2-4 per week, 5-6 per week, Once a day, 2-3 per day, 4-5 per day and 6+ per day.

Secondary

MeasureTime frameDescription
SmokingBaselineSmoking status will be evaluated as smoker, non-smoker or ex-smoker.
Meal timingsBaselineMeal timings will be captured using the Food Timing Questionnaire.
SleepBaselineQuestions from the Pittsburgh Sleep Quality Index will be used to evaluate sleep quality, latency and duration. Sleep quality: is measured on a 4-point scale ranging from very bad to very good. Sleep latency: participants will indicate the number of minutes taken to fall asleep on a weekday and weekend day. The 6-point scale ranges from 0-10 minutes to 60+ minutes. Sleep duration: participants will indicate the number of hours of actual sleep that are obtained on a weekday/weekend day.
General HealthBaselineGeneral health will be examined based on the presence of health conditions such as obesity, cardiovascular disease, diabetes etc.
Dietary habitsBaselineDietary habits will be evaluated based on the inclusion and exclusion of food items from diet, beliefs around diets and following specific diets as means to improve psoriasis.
Demographic characteristicsBaselineThe demographic characteristics assessed include age, gender and ethnicity.
Physical Activity (PA)BaselineThe International Physical Activity Questionnaire (IPAQ) categorises PA into vigorous intensity, moderate intensity and walking. The frequency (number of days/week) and the duration (number of hours) for each PA category will determine the participant's PA level: Health Enhancing Physical Activity (HEPA)=vigorous intensity physical activity is undertaken on at least 3 days/ week with a minimum of 1500 metabolic equivalent (MET) minutes/week or with 7 or more days of any combination of walking, moderate or vigorous intensity activities with a minimum of 3000 MET minutes/week. Minimally active (any one of the following)=3 or more days of vigorous activity with at least 20 minutes/day, 5 or more day of moderate intensity or walking at least 30 minutes/day, or 5 or more days of combination of walking, moderate or vigorous intensity activities with a minimum of 600 MET minutes/week. Inactive=no activity is reported or if some activity is reported but does not meet the above criteria.
AlcoholBaselineThe frequency and units of alcohol intake will be examined using the Alcohol Use Disorders Identification Test Consumption (AUDIT-C).

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026